44282 Federal Register / Vol. 83, No. 169 / Thursday, August 30, 2018 / Notices 

patients face a debilitating and often 

time fatal course of the disease. 

• Anti-complement drugs (including 

eculizumab) has the potential to treat 

CHAPLE disease. 

Development Stage 

• Pre-clinical. 

• Clinical. 

Inventors 

Dr. Michael J. Lenardo (NIAID), Dr. 

Helen Su (NIAID), Ahmet Ozen (NIAID), 

William A. Comrie (NIAID), Mr. Rico C. 

Ardy (CeMM, Austria), and Dr. Kaan 

Boztug (CeMM, Austria). 

Intellectual Property 

HHS Reference No. E–251–2016/0, 

U.S. Provisional Patent Application 

Number 62/394,630, filed September 14, 

2016, and PCT/US2017/051413 filed 

September 13, 2017. 

Licensing Contact 

Yogikala Prabhu, Ph.D., 301–761– 

7789; prabhuyo@niaid.nih.gov. 

Collaborative Research Opportunity 

The National Institute of Allergy and 

Infectious Diseases is seeking statements 

of capability or interest from parties 

interested in collaborative research to 

further develop, evaluate or 

commercialize the use of Eculizumab or 

other complement inhibitory drugs for 

the treatment of CHAPLE. For 

collaboration opportunities, please 

contact Yogikala Prabhu, Ph.D., 301– 

761–7789; prabhuyo@niaid.nih.gov. 

Dated: August 18, 2018. 

Suzanne M. Frisbie, 

Deputy Director, Technology Transfer and 

Intellectual Property Office, National Institute 

of Allergy and Infectious Diseases. 

[FR Doc. 2018–18779 Filed 8–29–18; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Center for Scientific Review; Notice of 

Closed Meetings 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The contract proposals and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the contract 

proposals, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; Shared and 

High-end Mass Spectrometers. 

Date: September 20–21, 2018. 

Time: 11:00 a.m. to 4:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Hotel Nikko San Francisco, 222 

Mason Street, San Francisco, CA 94102. 

Contact Person: Sudha Veeraraghavan, 

Ph.D., Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Bethesda, MD 

20892, 301–435–1504, 

sudha.veeraraghavan@nih.gov. 

Name of Committee: Surgical Sciences, 

Biomedical Imaging and Bioengineering 

Integrated Review Group; Surgery, 

Anesthesiology and Trauma Study Section. 

Date: September 26–27, 2018 

Time: 8:00 a.m. to 5:00 p.m. 

Agenda: To review and evaluate grant 

applications 

Place: Residence Inn Bethesda, 7335 

Wisconsin Avenue, Bethesda, MD 20814. 

Contact Person: Weihua Luo, MD, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 5114, 

MSC 7854, Bethesda, MD 20892, (301) 435– 

1170, luow@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; PAR Panel: 

Neural regulation of Cancer. 

Date: September 26, 2018. 

Time: 12:00 p.m. to 4:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6701 

Rockledge Drive, Bethesda, MD 20892 

(Virtual Meeting). 

Contact Person: Rolf Jakobi, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 6187, 

MSC 7806, Bethesda, MD 20892, 301–495– 

1718, jakobir@mail.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.306, Comparative Medicine; 

93.333, Clinical Research, 93.306, 93.333, 

93.337, 93.393–93.396, 93.837–93.844, 

93.846–93.878, 93.892, 93.893, National 

Institutes of Health, HHS) 

Dated: August 23, 2018. 

David D. Clary, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2018–18772 Filed 8–29–18; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Center for Advancing 

Translational Sciences; Notice of 

Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Center for 

Advancing Translational Sciences Special 

Emphasis Panel CTSA. 

Date: September 13–14, 2018. 

Time: 8:00 a.m. to 5:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Bethesda North Marriott Hotel & 

Conference Center, Brookside Conference 

Rooms A & B, 5701 Marinelli Road, 

Rockville, MD 20852. 

Contact Person: Victor Henriquez, Ph.D., 

Scientific Review Officer, Office of Scientific 

Director, National Center for Advancing 

Translational Sciences (NCATS), National 

Institutes of Health, 6701 Democracy Blvd., 

Democracy 1, Room 1080, Bethesda, MD 

20892–4878, 301–435–0813, henriquv@

mail.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.859, Pharmacology, 

Physiology, and Biological Chemistry 

Research; 93.350, B—Cooperative 

Agreements; 93.859, Biomedical Research 

and Research Training, National Institutes of 

Health, HHS) 

Dated: August 23, 2018. 

David D. Clary, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2018–18773 Filed 8–29–18; 8:45 am] 

BILLING CODE 4140–01–P 


amozie on DSK3GDR082PROD with NOTICES1